Core Insights - Y-mAbs Therapeutics, Inc. is set to report its first quarter 2025 results on May 13, 2025, before market opening [1] - A conference call and webcast will be held on the same day at 8:00 a.m. ET to discuss the results, with a live audio webcast available on the company's Investor Relations website [2] Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment [3] - The company utilizes advanced technologies such as the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies from the Y-BiClone platform [3] - Y-mAbs has a broad product pipeline, including DANYELZA® (naxitamab-gqgk), which is the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma in specific patient conditions [3]

Core Insights - Kraig Biocraft Laboratories, Inc. is successfully progressing towards its 2025 production scale-up targets, having completed its March/April spider silk production run and currently advancing in its May production cycle [1][3][4] Group 1: Production Progress - The company has met internal performance benchmarks and production targets for March and April, indicating confidence in its expanded capacity and workflow improvements [3][4] - May's production is already in progress, maintaining momentum towards achieving full-year production capacity goals [4][5] Group 2: Strategic Goals - Kraig Labs aims to transition recombinant spider silk from pilot-scale production to commercial viability across multiple markets, supporting its broader strategy [4][5] - The company emphasizes the importance of consistent execution and focus from its teams in Vietnam and the U.S. to strengthen manufacturing capabilities [5] Group 3: Company Background - Kraig Biocraft Laboratories is recognized as a leading developer of genetically engineered spider silk-based fiber technologies, with significant scientific breakthroughs impacting the global textile industry [7]

Core Insights - Pasithea Therapeutics Corp. announced positive interim pharmacodynamic data from its Phase 1 trial of PAS-004, a macrocyclic MEK inhibitor targeting neurofibromatosis type 1 and other MAPK pathway-driven cancers [1][5] - The trial demonstrated up to 91% inhibition of pERK, confirming substantial target engagement and a favorable pharmacological profile [1][3] - One patient with stage 4 KRAS G12R mutated pancreatic cancer showed a tumor volume reduction of -9.8% over 5 months of treatment with PAS-004 [1][4] Pharmacodynamic Data - Inhibition of ERK phosphorylation (pERK) is a recognized biomarker for assessing MEK inhibitor activity, with measurements taken from patients at baseline and day 22 [2] - The results indicated robust pERK inhibition, with reductions of up to 91% at the 8mg dose level, aligning with previous PK/PD models [3] Clinical Observations - Preliminary clinical observations showed several patients achieving stable disease and tumor shrinkage while on PAS-004 treatment [4] - The ongoing Phase 1 trial is a multi-center, open-label, dose escalation study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with MAPK pathway-driven advanced solid tumors [5] Company Overview - Pasithea Therapeutics is focused on developing innovative treatments for central nervous system disorders, RASopathies, and MAPK pathway-driven tumors [6]

Core Insights - Xometry, Inc. reported strong financial results for Q1 2025, with a record revenue of $151 million, representing a 23% year-over-year increase, driven by robust marketplace growth [5][7] - The company achieved a significant improvement in Adjusted EBITDA, which reached $0.1 million, reflecting a $7.5 million year-over-year improvement [5][6] - Xometry's marketplace revenue grew by 27% year-over-year to $136 million, indicating a 700 basis point acceleration from Q4 2024, primarily due to strong U.S. enterprise growth [5][6] Financial Highlights - Q1 2025 revenue was $150.971 million, up from $122.690 million in Q1 2024, marking a 23% increase [7] - Gross profit for Q1 2025 increased by 18% year-over-year to $56.331 million [7] - The net loss attributable to common stockholders decreased to $15.078 million from $16.616 million year-over-year, a 9% improvement [7] - Non-GAAP net income for Q1 2025 was $0.828 million, compared to a non-GAAP net loss of $5.742 million in Q1 2024 [6][7] Business Highlights - Active Buyers increased by 22% year-over-year, from 58,504 as of March 31, 2024, to 71,454 as of March 31, 2025 [6][8] - The number of Marketplace Accounts with Last Twelve-Months Spend of at least $50,000 rose by 12%, from 1,381 to 1,545 [6][8] - Supplier services revenue for Q1 2025 was $14.618 million, a decrease of 6% year-over-year [6][7] Growth Initiatives - Xometry plans to expand its buyer and supplier networks, deepen enterprise engagement, and enhance supplier services as part of its growth initiatives for 2025 [5][6] - The company launched Instant Quoting for Injection Molding in the EU, improving sourcing options for customers [6] - Xometry achieved Cybersecurity Maturity Model Certification (CMMC Level 2), reinforcing its position as a trusted partner in the aerospace and defense industries [6] Financial Guidance - For Q2 2025, Xometry expects revenue between $155 million and $157 million, representing a year-over-year growth of 17-18% [10][14] - The company anticipates Adjusted EBITDA of approximately $1.0-2.0 million for Q2 2025, an improvement from a loss of $2.6 million in Q2 2024 [14] - For the full year 2025, Xometry raised its marketplace growth outlook to at least 22% and expects supplier services revenue to decline by approximately 5% year-over-year [14]

Optima Health to acquire Care first, a leading provider of mental health services, for a net consideration of £15,000, adding c.£3.7 million revenue to the GroupAcquisition provides Optima with increased scale in its Mental Health division and will complement its existing Employee Assistance Programme (“EAP”) service offering, bringing over 1,000 new customers, and c.40 employeesAligns with strategy of consolidating margin accretive businesses in areas with significant existing expertise, creating additiona ...

A Refreshing Brew Perfect for Life’s Unexpected Delays, Blue Point’s Delayed Pilsner is Now Available at Transit Hubs Across New York CityPATCHOGUE, N.Y., May 06, 2025 (GLOBE NEWSWIRE) -- Blue Point Brewing Co., a Tilray Brands, Inc., (NASDAQ: TLRY and TSX: TLRY) craft beer brand, announces the highly anticipated re-release of Delayed Pilsner, a beer crafted to soothe the soul of every New Yorker facing the inevitable delays of city life. Whether it’s 2 minutes or 2 hours, delays are scientifically proven t ...

Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-sta ...

MONTRÉAL, May 06, 2025 (GLOBE NEWSWIRE) -- Stella-Jones Inc. (TSX: SJ), (“Stella-Jones” or “the Company”) will hold a conference call to discuss its first quarter results: OPEN TO:Investors, analysts and all interested parties DATE:Wednesday, May 7, 2025 TIME:8:00 AM Eastern Daylight TimeLIVE WEBCAST:https://meetings.lumiconnect.com/400-108-123-801 CALL:(+1) 800 206-4400 THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKET OPENS THE DAY OF THE CONFERENCE CALL THROUGH GLOBE NEWSWIRE. Please log on or dial ...

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European Hematology Association 2025 Congress in June Following Positive Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Company Initiated Dosing of Fourth Cohort in Part A of Phase 1/2 Trial and Received Clearance of U.S. IND; Updated Data Expected to be Pre ...

Sharps also received an initial qualification purchase order for DisGard™ single-use Sharps Recovery System Company transitions to revenue producing with second purchase order, bringing total recent orders to approximately $500,000 for the quarter NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry ...